An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2013
At a glance
- Drugs EMZ 702; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 17 Jul 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 28 Aug 2006 The expected completion date for this trial is now 1 Aug 2007.
- 14 Oct 2005 New trial record.